Search Result

Results for "

ppar-

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (597) 11β-HSD (2) 17β-HSD (1) Acetyl-CoA Carboxylase (3) Acyltransferase (1) Adenosine Receptor (1) Adiponectin Receptor (1) Akt (20) Aldose Reductase (1) Aminopeptidase (1) AMPK (31) Amylases (1) Amyloid-β (7) Androgen Receptor (4) Angiotensin Receptor (4) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) AP-1 (1) Apolipoprotein (2) Apoptosis (73) Aryl Hydrocarbon Receptor (1) ATP Citrate Lyase (1) ATP-binding cassette (ABC) transporters (1) Autophagy (54) Bacterial (46) Bcl-2 Family (4) Biochemical Assay Reagents (6) Bombesin Receptor (1) c-Myc (1) Calcium Channel (4) CaMK (1) Cannabinoid Receptor (4) Carnitine Palmitoyltransferase (CPT) (5) Caspase (15) CaSR (1) CDK (1) Ceramidase (1) Collagen (1) Constitutive Androstane Receptor (3) COX (33) Cytochrome P450 (19) Dipeptidyl Peptidase (1) DNA Methyltransferase (1) DNA/RNA Synthesis (4) Drug Derivative (3) Drug Intermediate (5) Drug Isomer (1) Drug Metabolite (12) EGFR (1) Endogenous Metabolite (72) Environmental Pollutants (7) Epoxide Hydrolase (5) ERK (26) Estrogen Receptor/ERR (3) Eukaryotic Initiation Factor (eIF) (1) FABP (4) FAK (2) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (4) Ferroptosis (23) FLAP (3) Fluorescent Dye (1) Free Fatty Acid Receptor (8) Fungal (20) FXR (3) GABA Receptor (1) Glucocorticoid Receptor (1) GLUT (7) Glutathione Peroxidase (1) Glycosidase (5) GPR55 (2) GSK-3 (4) HDAC (2) Hedgehog (5) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Demethylase (1) HIV (2) HSV (8) iGluR (2) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (2) Insulin Receptor (1) Integrin (2) Interleukin Related (23) Isotope-Labeled Compounds (69) JNK (13) Keap1-Nrf2 (16) Leukotriene Receptor (6) Ligands for Target Protein for PROTAC (1) Lipase (3) Liposome (2) Lipoxygenase (2) LXR (6) MDM-2/p53 (1) MEK (2) Mitochondrial Metabolism (10) Mitophagy (1) MMP (6) MNK (1) Monoamine Oxidase (2) mTOR (4) NEDD8-activating Enzyme (1) NEKs (1) NF-κB (60) NO Synthase (20) NOD-like Receptor (NLR) (5) Nuclear Hormone Receptor 4A/NR4A (2) Organoid (1) P-glycoprotein (2) P2Y Receptor (1) p38 MAPK (17) PAK (9) Parasite (13) PARP (12) PCSK9 (2) PDHK (1) PERK (1) PGC-1α (6) PGE synthase (2) Phosphatase (4) Phosphodiesterase (PDE) (4) PI3K (12) PKA (2) PKC (2) PNPLA3 (1) Potassium Channel (6) Prolyl Endopeptidase (PREP) (2) Prostaglandin Receptor (7) PTEN (2) Pyroptosis (5) Raf (1) RAR/RXR (18) Ras (1) Reactive Oxygen Species (ROS) (32) Reference Standards (98) ROCK (4) ROR (1) SARS-CoV (1) Sirtuin (6) Small Interfering RNA (siRNA) (5) SOD (6) Src (3) STAT (7) Stearoyl-CoA Desaturase (SCD) (4) STING (3) Tau Protein (3) TGF-beta/Smad (4) TGF-β Receptor (2) TNF Receptor (11) Toll-like Receptor (TLR) (4) TRP Channel (15) VD/VDR (1) VEGFR (5) WDR5 (2) Wnt (5) β-catenin (4)
By Research Areas:	Cancer (209) Cardiovascular Disease (108) Endocrinology (22) Infection (68) Inflammation/Immunology (214) Metabolic Disease (395) Neurological Disease (99)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Nucleoside Analogs (1) Rat Pre-designed siRNA Sets (1) Inosine (1) Phospholipids (2) Mouse Pre-designed siRNA Sets (1) siRNA drugs (3) Human Pre-designed siRNA Sets (1) Cholesterol (1) siRNAs (6)

670

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

152

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Pirinixic acid 30+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent PPARα agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and PPARδ agonist, with an IC₅₀ of 1 nM for human PPARδ in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

Chiglitazar 1 Publications Verification Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

CDDO-Im 10+ Cited Publications RTA-403; TP-235; CDDO-Imidazolide	Keap1-Nrf2 PPAR Ferroptosis	Cancer
CDDO-Im (RTA-403) is an activator of Nrf2 and *PPAR, with K_is of 232 and 344 nM for PPARα and PPAR*γ .

Clofibrate 4 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPAR*γ, respectively.

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

L-165041 2 Publications Verification	PPAR	Metabolic Disease
L-165041 is a cell permeable PPARδ agonist, with K_is of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

BMS-687453 3 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective PPARα agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

GW 590735 1 Publications Verification	PPAR	Metabolic Disease
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

PPARα/γ agonist 1	PPAR	Metabolic Disease
PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC₅₀ values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .

PPARγ-IN-2	PPAR	Metabolic Disease
PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC₅₀: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .

PPAR agonist 5	PPAR	Inflammation/Immunology
PPAR agonist 5 (compound 4b) is a potent *PPAR* agonist with EC₅₀ values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

PPARA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PPAR	Others
PPARA Human Pre-designed siRNA Set A contains three designed siRNAs for PPARA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PPARα agonist 2	PPAR	Cardiovascular Disease
PPARα agonist 2 (compound 4u) is a potent and selective PPARα agonist with an EC₅₀ of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research .

Clofibrate (Standard) 4 Publications Verification	Reference Standards PPAR	Metabolic Disease
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPAR*γ, respectively.

PPARγ agonist 5	PPAR	Cancer
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases .

PPARδ/γ agonist 1 sodium	PPAR	Neurological Disease
PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer’s disease .

PPARγ agonist 11	PPAR	Metabolic Disease
PPARγ agonist 11 (compound 20) is a selective agonist of PPARγ (EC₅₀: 0.1 μM) .

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

PPAR agonist 7	PPAR Adenosine Receptor Fatty Acid Synthase (FASN) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC₅₀ = 1.51 μM), PPARδ (EC₅₀ = 1.11 μM), and PPARγ (EC₅₀ = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

PPARγ/δ modulator 1	PPAR	Metabolic Disease
PPARγ/δ modulator 1 (compound 3e) is a potent *PPAR* modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with K_i values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC₅₀ of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .

GW0742 (Standard) GW610742 (Standard)	PPAR Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

Chiglitazar sodium Carfloglitazar sodium	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

Rac-Pemafibrate Rac-K13675	PPAR	Inflammation/Immunology
Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC₅₀s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC₅₀s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .

GW409544	PPAR	Cardiovascular Disease Metabolic Disease
GW409544 is a potent PPARα and PPARγ activator, with EC₅₀ values of 2.3 nM and 0.28 nM for PPARα and PPARγ, respectively. GW409544 can be used for the research of metabolic and cardiovascular diseases .

PPARα agonist 6	PPAR	Cardiovascular Disease Metabolic Disease
PPARα agonist 6 (Compound 15) is a PPARα agonist. PPARα agonist 6 can be used in the research of dyslipidemia .

PPARγ agonist 6	PPAR	Cancer
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of PPARγ. PPARγ agonist 6 has the potential for the research of cancer diseases .

17(S)-HDHA	PPAR	Metabolic Disease
17(S)-HDHA is a pro-resolving mediator (SPM). 17(S)-HDHA slightly activats PPARγ, PPARα and PPARδ .

Pparδ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
Pparδ agonist 1 is a *PPAR-δ* agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

PPARγ agonist 20	PPAR Glutathione Peroxidase SOD TNF Receptor Interleukin Related NF-κB	Infection Metabolic Disease Endocrinology
PPARγ agonist 20 is a potent, orally active *PPAR-γ* agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

DB-959 pparδ/γ agonist 1	PPAR	Neurological Disease
DB-959 (PPARδ/γ agonist 1) is a potent *PPAR* agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD). .

PPAR agonist 4	PPAR	Others
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC₅₀s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .

PPAR agonist 6	PPAR	Metabolic Disease
PPAR agonist 6 (compound 5a) is an agonist of *PPAR* with EC₅₀ values of 3.6 μM, 2.6 μM, and 2.7 μM for PPARα, PPARβ/δ, and PPARγ, respectively. PPAR agonist 6 represses the transactivation of the TNFα-dependent NF-κB-driven reporter in L929 cells .

*HSD17B13/PPAR* modulator-1**	17β-HSD PPAR	Metabolic Disease Inflammation/Immunology
HSD17B13/PPAR modulator-1 (Compound 17) is a *HSD17B13/PPAR* multitarget modulator. HSD17B13/PPAR modulator-1 is an inhibitor of HSD17B13, with its IC₅₀ value being 0.91 μM. HSD17B13/PPAR modulator-1 is a *PPAR* agonist, with the EC₅₀ values for PPARα, PPARδ, and PPARγ being 1.55, 0.12, and 0.01 μM respectively. HSD17B13/PPAR modulator-1 can significantly improve liver function, regulate lipid metabolism, alleviate fibrosis, and exert antioxidant and anti-inflammatory effects in the model of metabolic dysfunction-related steatohepatitis (MASH). HSD17B13/PPAR modulator-1 can be used for the study of MASH .

*ABP/PPAR* modulator 1**	FABP PPAR	Metabolic Disease Inflammation/Immunology
ABP/PPAR modulator 1 is an orally active FABP and *PPAR* multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

*(E/Z)-ABP/PPAR* modulator 1**	FABP PPAR	Metabolic Disease Inflammation/Immunology
(E/Z)-ABP/PPAR modulator 1 is a mixture of the E and Z isomers of ABP/PPAR modulator 1 (HY-172883). ABP/PPAR modulator 1 is an orally active FABP and *PPAR* multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

Ppara Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PPAR	Others
Ppara Rat Pre-designed siRNA Set A contains three designed siRNAs for Ppara gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ppara Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PPAR	Others
Ppara Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ppara gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Bezafibrate-d4 BM15075-d₄	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

1,095 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,095 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

4,634 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,634 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate

Fluorescent Dye

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-B1773A

Sodium propionate

3 Publications Verification

Biochemical Assay Reagents

Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease .

HY-107737

1,2-DLPC 2 Publications Verification 1,2-Dilauroyl-sn-glycero-3-phosphocholine	Biochemical Assay Reagents
1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells .

HY-Y1325H

Sodium acetate trihydrate, meets analytical specification of Ph. Eur. BP USP FCC E262, ≤0.00002% Al

4 Publications Verification

Biochemical Assay Reagents

Sodium acetate trihydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Sodium acetate trihydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Sodium acetate trihydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Sodium acetate trihydrate regulates energy metabolism. Sodium acetate trihydrate has anticancer activity against gastric cancer. Sodium acetate trihydrate induces writhing reaction and ulcerative colitis. Sodium acetate trihydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain .

HY-Y0319G

Magnesium acetate tetrahydrate

4 Publications Verification

Biochemical Assay Reagents

Magnesium acetate tetrahydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate regulates energy metabolism. Magnesium acetate tetrahydrate has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain .

HY-Y0319D

Acetic acid lead

Biochemical Assay Reagents

Acetic acid lead is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Acetic acid lead exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Acetic acid lead regulates energy metabolism. Acetic acid lead has anticancer activity against gastric cancer. Acetic acid lead induces writhing reaction and ulcerative colitis. Acetic acid lead can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain .

HY-Y0319G1

Magnesium acetate tetrahydrate, for molecular biology

Biochemical Assay Reagents

Magnesium acetate tetrahydrate, for molecular biology is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate, for molecular biology activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate, for molecular biology exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate, for molecular biology regulates energy metabolism. Magnesium acetate tetrahydrate, for molecular biology has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate, for molecular biology induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate, for molecular biology can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain .

HY-17356G

Fenofibrate

Biochemical Assay Reagents

HY-B1773AR

Sodium propionate (Standard)

Biochemical Assay Reagents

Sodium propionate (Standard) is the analytical standard of Sodium propionate. This product is intended for research and analytical applications. Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease .

HY-107737R

1,2-DLPC (Standard)

1,2-Dilauroyl-sn-glycero-3-phosphocholine (Standard)

Biochemical Assay Reagents

1,2-DLPC (Standard) is the analytical standard of 1,2-DLPC (HY-107737). This product is intended for research and analytical applications. 1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breaK_down and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells .

Cat. No.	Product Name	Target	Research Area

HY-12557

γ-Glutamylvaline γ-Glu-Val	Endogenous Metabolite CaSR Wnt TNF Receptor Interleukin Related PPAR β-catenin	Inflammation/Immunology
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances *adiponectin/PPARγ* in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

HY-P11589

PIISVYWK	PPAR Reactive Oxygen Species (ROS) Keap1-Nrf2	Metabolic Disease
PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity .

Species:	Human (10) Mouse (2)
Tag:	His (10) Tag Free (1) GST (2)
Source:	HEK293 (1) Sf9 insect cells (2) P. pastoris (1) E. coli (8)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P7999

	PPAR gamma Protein, Human (His) Maximum Cited Publications 7 Publications Verification ppar-γ-LBD	Human	E. coli
	PPAR gamma LBD Protein, Human (His) is a His-fused PPAR-gamma-LBD protein expressed by E. coli, approximately 32.6 kDa. PPAR gamma LBD Protein can be used in the ligand screening assays, western blotting, and ELISA, et al.

HY-P7996

	PPAR alpha Protein, Human (His) 2 Publications Verification pparA, ppar-α	Human	E. coli
	PPAR alpha Protein, human (His), a member of the nuclear receptor family, is a transcription factor that regulates the expression of genes related to lipid metabolism in a ligand-dependent manner.

HY-P702843

	PPAR alpha Protein, Mouse (His) 1 Publications Verification pparA, ppar-α	Mouse	E. coli
	PPAR alpha Protein, Mouse (His), a member of the nuclear receptor family, is a transcription factor that regulates the expression of genes related to lipid metabolism in a ligand-dependent manner.

HY-P700275

	PPAR gamma Protein, Human (C-His, solution) ppar-γ-LBD	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (C-His, solution) is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with C-6*His labeled tag.

HY-P701336

	PPAR gamma Protein, Human pparG; Peroxisome proliferator-activated receptor gamma; ppar-gamma; Nuclear receptor subfamily 1 group C member 3	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with tag free.

HY-P705437

	PPAR gamma Protein, Mouse (His) pparg; Nr1c3; Peroxisome proliferator-activated receptor gamma; ppar-gamma; Nuclear receptor subfamily 1 group C member 3	Mouse	E. coli

HY-P704244

	PPARD Protein, Human (His) FAAR; MGC3931; NR1C2; NUC1; NUCI; NUCII; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferative activated receptor delta; Peroxisome proliferator-activated receptor beta (ppar-beta); Peroxisome proliferator-activated receptor beta; Peroxisome proliferator-activated receptor delta; ppar beta; ppar-beta; ppar-delta; pparB; ppard; pparD_HUMAN	Human	E. coli
	PPARD protein is a ligand-activated transcription factor that critically mediates energy metabolism in adipose tissue. As a receptor, it selectively binds peroxisome proliferators, including hypolipidemic drugs and fatty acids, and preferentially binds polyunsaturated substances. PPARD Protein, Human (His) is the recombinant human-derived PPARD protein, expressed by E. coli, with N-6*His labeled tag.

HY-P7S0363

	PPARD Protein, Human (HEK293, His) Peroxisome proliferator-activated receptor delta; ppar-delta; NUCI; Nuclear hormone receptor 1 (NUC1); Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta (ppar-beta);	Human	HEK293
	PPARD protein is a ligand-activated transcription factor that critically mediates energy metabolism in adipose tissue. As a receptor, it selectively binds peroxisome proliferators, including hypolipidemic drugs and fatty acids, and preferentially binds polyunsaturated substances. PPARD Protein, Human (HEK293, His) is the recombinant human-derived PPARD protein, expressed by HEK293, with C-6*His labeled tag.

HY-P702572

	PPAR gamma Protein, Human (P.pastoris, His) CIMT1, GLM1, NR1C31, pparG2, pparG5, ppargamma, pparG	Human	P. pastoris
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (P.pastoris, His) is the recombinant human-derived PPAR gamma protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P76523

	NRBF2 Protein, Human (sf9, His-GST) Nuclear receptor-binding factor 2; Comodulator of ppar and RXR; COPR	Human	Sf9 insect cells
	NRBF2 protein may regulate transcriptional activation through target nuclear receptors and act as a transcriptional activator in vitro. It participates in starvation-induced autophagy, binding to PI3K complex I (PI3KC3-C1) and stabilizing its assembly. NRBF2 Protein, Human (sf9, His-GST) is the recombinant human-derived NRBF2 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P73701

	PPAR gamma Protein, Human (sf9, His-GST) CIMT1; GLM1; NR1C31; pparG2; pparG5; ppargamma; pparG	Human	Sf9 insect cells
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (sf9, His-GST) is the recombinant human-derived PPAR gamma protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P790012Y

	PPAR-gamma Protein, Human (271a.a, His, solution) CIMT1; GLM1; NR1C31; pparG2; pparG5; ppargamma; pparG	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR-gamma Protein, Human (271a.a, His, solution) is the recombinant human-derived PPAR-gamma protein, expressed by E. coli , with labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (6) Rabbit (10)
Reactivity:	Human (13) Bovine (1) Rat (12) Mouse (12) Rabbit (1) Sheep (1) Goat (1) Dog (1) Pig (1)
Application:	IHC-P (5) ICC/IF (8) IP (1) IHC-F (2) WB (15) ELISA (5)
Isotype:	IgG,Kappa (1) IgG (11) IgG1 (1)
Conjugation:	Non-conjugated (16)
Clonality:	Polyclonal (3) Monoclonal (11) Recombinant (5)
Modification:	Unmodified (14)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86449

	PPAR alpha Antibody (YA6141) pparA; NR1C1; ppar; Peroxisome proliferator-activated receptor alpha; ppar-alpha; Nuclear receptor subfamily 1 group C member 1	WB, IP, ELISA	Human, Mouse, Rat
	PPAR alpha Antibody (YA6141) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR alpha.

HY-P80436

	PPAR gamma Antibody (YA122) 1 Publications Verification	WB	Human, Rat
	PPAR gamma Antibody (YA122) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR gamma.

HY-P87712

	PPAR-γ Antibody (YA7397)	WB, IHC-P, ICC/IF, ELISA	Human, Mouse
	PPAR-γ Antibody (YA7397) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to PPAR-γ.

HY-P88048

	PPAR Delta Antibody (YA7733)	WB, ICC/IF
	PPAR Delta Antibody (YA7733) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR Delta.

HY-P80871

	PPAR alpha Antibody 1 Publications Verification pparA; NR1C1; ppar; Peroxisome proliferator-activated receptor alpha; ppar-alpha; Nuclear receptor subfamily 1 group C member 1	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	PPAR alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PPAR alpha.

HY-P88048A

	PPAR Delta Antibody (YA7733)(PBS only)	WB, ICC/IF
	PPAR Delta Antibody (YA7733) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR Delta.

HY-P85702

	PPAR gamma Antibody (YA5394) Peroxisome proliferator-activated receptor gamma; ppar-gamma; Nuclear receptor subfamily 1 group C member 3;	IHC-P, WB	Human, Mouse, Rat
	PPAR gamma Antibody (YA5394) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR gamma.

HY-P85753

	PPAR Delta Antibody (YA5445) Peroxisome proliferator-activated receptor delta; ppar-delta; NUCI; Nuclear hormone receptor 1; NUC1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; ppar-beta;	ICC/IF, IHC-P	Human, Rat, Mouse
	PPAR Delta Antibody (YA5445) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR Delta.

HY-P85457

	PPAR gamma Antibody (YA5149) pparG; NR1C3; Peroxisome proliferator-activated receptor gamma; ppar-gamma; Nuclear receptor subfamily 1 group C member 3	WB, ICC/IF	Human, Mouse, Rat, Bovine, Dog, Goat, Pig, Rabbit, Sheep
	PPAR gamma Antibody (YA5149) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR gamma.

HY-P80783

	PGC1 alpha Antibody 1 Publications Verification pparGC1A; LEM6; PGC1; PGC1A; pparGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; ppar-gamma coactivator 1-alpha; pparGC-1-alpha; Ligand effect modulator 6	WB	Human, Mouse, Rat
	PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PGC1 alpha.

HY-P80783A

	PGC1 alpha Antibody (YA7180) 1 Publications Verification pparGC1A; LEM6; PGC1; PGC1A; pparGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; ppar-gamma coactivator 1-alpha; pparGC-1-alpha; Ligand effect modulator 6	WB	Human, Mouse, Rat
	PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha.

HY-P85326

	PGC1 alpha Antibody (YA5018) pparGC1A; LEM6; PGC1; PGC1A; pparGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; ppar-gamma coactivator 1-alpha; pparGC-1-alpha; Ligand effect modulator 6	WB	Mouse, Rat
	PGC1 alpha Antibody (YA5018) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to PGC1 alpha.

HY-P80783AA

	PGC1 alpha Antibody (YA7180)(PBS only) pparGC1A; LEM6; PGC1; PGC1A; pparGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; ppar-gamma coactivator 1-alpha; pparGC-1-alpha; Ligand effect modulator 6	WB	Human, Mouse, Rat
	PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha.

HY-P83728

	PGC1 alpha+beta Antibody (YA3458) LEM6 antibody; Ligand effect modulator 6 antibody; PERC antibody; Peroxisome proliferative activated receptor, gamma, coactivator 1 antibody; PGC 1 alpha antibody; PGC-1-beta antibody; PGC-1-related estrogen receptor alpha coactivator antibody; PGC1 antibody; PGC1A antibody; PGC1v antibody; ppar gamma coactivator 1 alpha antibody; ppar gamma coactivator-1 beta antibody; pparGC 1 alpha antibody; pparGC-1-beta antibody; pparGC1 antibody; pparGC1A antibody; ppargc1b antibody; PRGC1_HUMAN antibody; PRGC2_HUMAN antibody;	WB	Human, Mouse, Rat
	PGC1 alpha+beta Antibody (YA3458) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha+beta.

HY-P80872

	PPAR gamma Antibody CIMT1; GLM1; NR1C3; Nuclear receptor subfamily 1 group C member 3; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome prolife	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	PPAR gamma Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PPAR gamma.

HY-P85872

	MED1 Antibody (YA5564) Mediator of RNA polymerase II transcription subunit 1; Activator-recruited cofactor 205 kDa component; ARC205; Mediator complex subunit 1; Peroxisome proliferator-activated receptor-binding protein; PBP; ppar-binding protein; Thyroid hormone receptor-associated protein complex 220 kDa component; Trap220; Thyroid receptor-interacting protein 2; TR-interacting protein 2; TRIP-2; Vitamin D receptor-interacting protein complex component DRIP205;	WB, ICC/IF, ELISA	Human
	MED1 Antibody (YA5564) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MED1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-173115

15-LOX-IN-2		Alkynes
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .

Cat. No.	Product Name		Classification

HY-N4103

Fucosterol 2 Publications Verification		Cholesterol
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

HY-132591

Inclisiran Maximum Cited Publications 7 Publications Verification ALN-PCSsc		siRNAs siRNA drugs
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-132591A

Inclisiran sodium Maximum Cited Publications 7 Publications Verification ALN-PCSsc sodium		siRNAs siRNA drugs
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-107737

1,2-DLPC 2 Publications Verification 1,2-Dilauroyl-sn-glycero-3-phosphocholine		Phospholipids
1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells .

HY-143221

AS-Inclisiran sodium		siRNAs siRNA drugs
AS-Inclisiran sodium is the antisense of Inclisiran (HY-132591). Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-128671

6-Thioinosine 6TI; 6-Mercaptopurine riboside		Nucleoside Analogs Inosine
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction .

HY-W440983

SDPC PC(18:0/22:6); DHA-PC; 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine		Phospholipids
SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research .

HY-RS10919

PPARA Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PPARA Human Pre-designed siRNA Set A contains three designed siRNAs for PPARA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10921

Ppara Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Ppara Rat Pre-designed siRNA Set A contains three designed siRNAs for Ppara gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10920

Ppara Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Ppara Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ppara gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ppar-

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products